Author of

• 18502

  +

  P3.02c - Poster Session with Presenters Present (ID 472)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 18515

    +

    P3.02c-013 - Combination Therapy of Oncolytic Herpes Simplex Virus Type 1 with Erlotinib in a Human Lung Cancer Xenograft Model (ID 5848)

    14:30 - 14:30  |  Author(s): Y. Sakata
    • Abstract

    Background:
    Despite the development of a number of new targeted therapies, lung cancer remains the leading cause of cancer-related death worldwide. The use of oncolytic herpes simplex virus type 1 (HSV-1) has been shown to be an effective therapeutic approach for a variety of cancer in preclinical models. A third generation oncolytic HSV-1, G47Δ, is currently used in multiple clinical trials in Japan.
    
    Methods:
    In this study, we evaluated the efficacy and safety of G47Δ when used in combination with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in lung cancer xenograft models in mice. Human lung cancer cell line A549 subcutaneous tumor-bearing mice were treated with G47Δ and erlotinib, each alone or in combination, and effects on tumor volume were determined. The toxicity was evaluated by body weight changes.
    
    Results:
    In this subcutaneous tumor model, combination therapy resulted in the inhibition of tumor growth without toxicity to a greater extent than that using each agent alone.
    
    Conclusion:
    These findings suggest that combination therapy of G47Δ and erlotinib may be a new treatment strategy against human lung cancer.